{"filings":[{"id":677761,"accession_number":"0000724004-26-000039","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2026-05-27T12:00:13+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q4 revenue up 2.6% but net loss $4.1M; BPD revenue falls 29.9% on export controls","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $63.7M (+2.6% YoY); net loss $4.1M ($0.75 loss per share) vs prior year loss of $7.1M.","Non-GAAP AOI margin 28.7% (vs 19.7% last year) driven by SDC backlog clearance and cost actions.","BPD division revenue declined 29.9% due to export controls delaying Peptide system shipments; BPD core organic -31.6%.","SDC organic growth 17.7% aided by ~$2M backlog reduction; full-year SDC organic 8.7%.","Repaid $14.7M debt in Q4; net leverage ratio 2.11; CFO expects overall core organic growth positive in Q1 FY27."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114054,"accession_number":"0000724004-26-000030","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Gary Owens to depart by April 13; remains non-executive through June 22","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Owens steps down as President and CEO effective ~April 13, 2026; stays in non-executive role until June 22, 2026.","Owens resigned from the Board on March 20, 2026; no disagreement with Company cited.","Transition Agreement provides severance of 1x base salary ($815K) plus 1x target bonus ($896.5K), prorated FY27 bonus, and accelerated vesting of certain equity awards.","Owens eligible for up to $10,000 legal fee reimbursement; severance conditioned on signing a release of claims.","No successor CEO has been named; Board is managing the transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114053,"accession_number":"0000724004-26-000020","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Mesa Labs appoints Siddhartha Kadia as CEO to succeed Gary Owens effective April 13, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gary Owens departs as President and CEO effective April 12, 2026; separation not due to any disagreement.","Dr. Siddhartha Kadia appointed as President and CEO and to the Board, effective April 13, 2026.","Kadia previously CEO of Calibre Scientific, PhenomeX/Berkeley Lights, and EAG Laboratories; over 20 years in life sciences.","Compensation: $850k base salary, annual bonus target at least 100% of base, initial equity awards of $3M RSUs and $3M target PSUs.","Board conducted comprehensive external search; Kadia's appointment part of long-term leadership strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114052,"accession_number":"0000724004-26-000015","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q3 revenue up 3.6% to $65.1M; net income surges 317% to $3.63M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $65.1M, +3.6% YoY; core organic growth 1.2%.","Operating income $7.98M, +38%; AOI $17.07M, +15.4%.","Net income $3.63M, diluted EPS $0.65 vs $0.16 YoY.","Repaid $8.7M debt; total net leverage ratio improved to 2.62.","BPD division led with 17.5% organic growth; CG China revenue down 57%."],"consensus_eps_estimate":null,"consensus_eps_actual":1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":185406000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130442,"accession_number":"0000724004-25-000012","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs 2Q26 revenue up 5%, net income down 27.8% on tariffs and China headwinds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $60.7M, +5.0% YoY; core organic growth 3.7%.","Net income $2.5M ($0.45 diluted EPS), down 27.8% from 2Q25.","Non-GAAP AOI excluding unusual items $15.2M, +6.1%; margin 25.1% vs 24.8%.","Clinical Genomics core organic -3.6%: China -58%; outside China +16.2%.","Annualized cost reductions of $3.2M; net savings $2.3M after reinvestment. Tariffs 70 bps of revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":120280000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146995,"accession_number":"0001437749-25-027659","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mesa Laboratories holds 2025 annual meeting; shareholders elect all seven director nominees and approve amendments","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 7 director nominees elected with >90% support; vote totals range from 4.69M to 4.85M for.","Baker Tilly ratified as independent auditor for FY2026 with 5,200,789 for (99.97% of votes cast).","Non-binding say-on-pay approved: 4,476,544 for (91.6% of votes cast excluding broker non-votes).","Amendment to 2021 Equity Incentive Plan approved: 4,601,685 for (94.2% of votes cast).","Board committee chairs appointed: Audit (Tripeny), Compensation (Capone), Nominating (Alltoft)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146994,"accession_number":"0001437749-25-027225","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["2.03","9.01"],"status":"ready","headline":"Mesa Laboratories draws $97M under credit facility to repay convertible notes due August 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Drew $97M under existing Credit Agreement to settle $97.5M of 1.375% Convertible Senior Notes maturing August 2025; total outstanding under credit facility now $108M.","Interest rate on credit facility currently 7.18%, expected to decrease with Fed rate reductions and an additional 25 bps when net leverage ratio falls below 3.0x (expected by Q3 FY2026).","Total net leverage ratio was 3.16 as of June 30, 2025; expected principal payments of ~$20M in Q2–Q4 FY2026 with higher payments in FY2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146993,"accession_number":"0001437749-25-024714","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Laboratories Reports First Quarter Fiscal 2026 Results","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues increased 2.4% to $59,543,000 for the quarter ended June 30, 2025.","Operating income decreased 45.1% to $3,064,000, impacted by FX and stock-based compensation.","Clinical Genomics division revenue fell 10.7% core organic as China revenues contracted 69%.","About $1.5M of expected Biopharmaceutical Development revenues shifted from Q1 to Q2 due to tariff surcharges.","Non-GAAP adjusted operating income (excluding unusual items) was $12,902, down 15.9% year-over-year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":59543000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165505,"accession_number":"0001437749-25-019696","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Mesa Labs auditor changes from Moss Adams to Baker Tilly after merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Moss Adams merged with Baker Tilly US, LLP effective June 3, 2025; Baker Tilly appointed as successor independent auditor.","No disagreements or reportable events with Moss Adams during fiscal 2025 or subsequent interim period.","Moss Adams' audit reports on FY2025 consolidated financials and internal controls were unqualified.","Audit Committee approved appointment of Baker Tilly; no prior consultations with Baker Tilly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165504,"accession_number":"0001437749-25-018585","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q4 revenue up 5.5% but net loss widens to $7.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $62.1M, up 5.5% YoY; core organic growth 6.3%.","GAAP net loss $7.1M ($1.31 diluted EPS) vs loss $3.6M in prior-year quarter.","Adjusted operating income excluding unusual items $12.3M, down 18% YoY.","Full fiscal year revenue $241M, up 11.5%; core organic growth 5.0%.","SDC division core organic growth 10.3%; CG division continued decline in China."],"consensus_eps_estimate":0.2822,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":240978000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183150,"accession_number":"0001437749-25-002661","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q3 revenue up 17.5% to $62.8M; core organic growth 13.2%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $62.8M (+17.5% YoY); non-GAAP core organic revenue +13.2%.","GAAP net loss $(1.68M) ($0.31 diluted); non-GAAP AOI ex unusual items $14.79M (+13.3%).","All four divisions grew: BPD +31.3% core organic, CS +18.9%, SDC +8.2%, CG +1.9% (3rd consecutive sequential rise).","Repaid $9.4M debt in Q3; net leverage ratio 3.20x; targeting below 3.0x by Q2 2026.","GKE acquisition contributed 4.9% inorganic growth and exceeded first-year expectations."],"consensus_eps_estimate":0.1632,"consensus_eps_actual":0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":178843000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199725,"accession_number":"0001437749-24-033744","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q2 revenue $57.8M (+8.8% YoY); core organic revs -2.8%; AOI margin 24.8%; net debt reduced by $7.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $57.8M (+8.8% YoY); net income $3.4M ($0.63 diluted EPS) vs. prior year loss.","Non-GAAP AOI ex-unusual items $14.4M, margin 24.8% (up 210 bps); core organic revs declined 2.8%.","BPD division core organic growth 27.9% (strong capital equipment); CG declined 26.5% (China/LDT headwinds).","Repaid $7.4M debt in Q2; Net Leverage Ratio improved to 3.26, targeting below 3.0x.","GKE acquisition (closed late 2023) contributed 11% revenue growth, ahead of initial expectations."],"consensus_eps_estimate":0.4454,"consensus_eps_actual":1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":116003000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215744,"accession_number":"0001437749-24-028898","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Mesa Labs names Moss Adams as new auditor, replacing RSM US LLP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee appointed Moss Adams as independent auditor for FY ending March 31, 2025, dismissing RSM effective immediately.","No disagreements with RSM or former auditor Plante & Moran on accounting principles or audit scope.","RSM's audit reports for FY 2024 and Plante & Moran's for FY 2023 were unqualified, with no adverse opinions.","Previously reported material weaknesses in internal control over financial reporting were noted in 8-K disclosures.","RSM furnished a letter agreeing with the Company's statements, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215743,"accession_number":"0001437749-24-028148","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mesa Laboratories shareholders elect all 7 director nominees, ratify RSM US LLP as auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected: John Sullivan, Gary Owens, Shannon Hall, Jenny Alltoft, Shiraz Ladiwala, Tony Tripeny, Mark Capone.","RSM US LLP ratified as independent auditor for FY ending March 31, 2025 with 4,992,593 votes for.","Non-binding advisory vote on executive compensation approved with 4,581,083 votes for.","Annual meeting held August 30, 2024; 5,096,365 of 5,409,163 eligible shares represented.","Broker non-votes of 255,479 on director elections and say-on-pay; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215742,"accession_number":"0001437749-24-024570","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q1 revenue $58.2M (+14.9%), EPS $0.62; operating income up 940%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $58.2M (+14.9% YoY); net income $3.4M (+717%); diluted EPS $0.62.","Non-GAAP core organic revenue growth 3.0%; AOI excl. unusual items $15.3M (+47%).","Divisions: BPD core organic growth 23.5%; CG declined 14.3% (China/US headwinds).","Repaid $9.4M debt; net leverage ratio reduced to 3.41 (target <3.0x).","GKE acquisition contributing above expectations; non-cash inventory step-up charges to end by 2Q25."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":58170000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235148,"accession_number":"0001437749-24-019257","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q4 net loss of $254.6M on $274.5M impairment; core organic revenues down 3.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $58.9M (+6% YoY); core organic revenue declined 3.5% due to headwinds in Clinical Genomics and Biopharma.","Full-year operating loss of $272.1M includes $274.5M non-cash impairment of goodwill and long-lived assets.","Non-GAAP AOI excluding unusual items rose 26.3% in Q4 to $14.9M; full-year AOI +0.7% to $50.5M.","Clinical Genomics division restructured with 17 position eliminations, expects ~$3M annual savings.","SDC division grew 37.3% (including GKE China acquisition); BPD and CG declined organically."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235147,"accession_number":"0001437749-24-011307","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Mesa Labs amends credit facility, adds $75M term loan; repurchases $75M of 2025 convertible notes at discount","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended credit agreement: $75M term loan + $125M revolver, matures April 2029, interest at SOFR + 1.5%-3.5%.","Repurchased $75M aggregate principal of 1.375% convertible notes due 2025 for $71.25M cash; closing expected April 11, 2024.","After repurchase, $97.5M of 2025 notes remain outstanding; total credit facility debt $125.5M ($75M term loan + $50.5M revolver).","CFO aims to reduce total net leverage ratio to below 3.0x over next 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235146,"accession_number":"0001437749-24-010537","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["2.06","9.01"],"status":"ready","headline":"Mesa Labs expects $271M non-cash impairment charge for FY2024, impacting two divisions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-cash impairment of ~$271M for Clinical Genomics and Biopharmaceutical Development divisions in Q4 FY2024.","Goodwill impairment of ~$123M ($98M Clinical Genomics, $25M Biopharm Dev) and intangible asset impairment of ~$148M ($114M and $34M).","Driven by restructuring (eliminated 17 positions), loss of Sema4 as customer, macro uncertainty, and higher discount rates.","Non-cash charge does not affect cash flows from operations; final amounts subject to change upon 10-K filing.","Management cites new strategies, downward revenue revisions, and elevated interest rates as key factors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252965,"accession_number":"0001437749-24-003052","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q3 revenue down 1.5%; operating loss of $67K; core organic revenue declines 9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $53.5M, down 1.5% YoY; core organic revenue declined 9%.","Operating loss of $67K vs income $3.2M prior year; net income $2.1M up 369% on unusual items.","Non-GAAP adjusted operating income excl. unusual items $12.0M, down 6.8% YoY but up 7.3% sequentially.","Clinical Genomics down 19% on China anti-corruption; Biopharm capital constrained but consumables +16.5%.","Calibration Solutions revenue +12.9%, gross margin +600 bps; GKE acquisition added $3.8M revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":157283000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252964,"accession_number":"0001437749-24-000821","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Mesa Laboratories appoints Mark Capone to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 6 to 7 members; Capone appointed effective Jan 5, 2024.","Capone most recently served as CEO/President of Myriad Genetics; also 17 yrs at Eli Lilly.","Appointed to Audit Committee, replacing Shiraz Ladiwala.","Capone determined independent under Nasdaq and SEC rules.","No related party transactions with Mesa reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}